FDA Panels Reject Boxed Warning on Suicidality Risk for Epilepsy Drugs

BELTSVILLE, MD. — A boxed warning about an increased suicidality risk with the use of antiepileptic drugs should not be added to the labels of drugs in this class, but patients prescribed these drugs should receive information about this risk with every prescription, according to the majority of two federal advisory panels.